Old Web
English
Sign In
Acemap
>
authorDetail
>
Deborah Chiles
Deborah Chiles
Pfizer
Desvenlafaxine
Psychiatry
Major depressive disorder
Rating scale
Adverse effect
4
Papers
28
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Re: “Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research” by Strawn JR and Croarkin PE (J Child Adolesc Psychopharmacol 2018;28:(5)363)
2019
Journal of Child and Adolescent Psychopharmacology
Karen L. Weihs
Dalia Wajsbrot
Deborah Chiles
Sara Ramaker
Phil Chappell
Show All
Source
Cite
Save
Citations (1)
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
2017
Journal of Child and Adolescent Psychopharmacology
Karen L. Weihs
William Rory Murphy
Richat Abbas
Deborah Chiles
Richard D. England
Sara Ramaker
Dalia Wajsbrot
Show All
Source
Cite
Save
Citations (13)
Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder
2016
Journal of Child and Adolescent Psychopharmacology
Robert L. Findling
James Groark
Karen A. Tourian
Sara Ramaker
Deborah Chiles
Lingfeng Yang
Alice I. Nichols
Show All
Source
Cite
Save
Citations (3)
1